Truseltiq Second Targeted Therapy Approved for Metastatic Cholangiocarcinoma Harboring FGFR2 Alterations

August 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology - Cholangiocarcinoma, FDA Approvals, Conference Highlights ASCO

On May 28, 2021, the FDA accelerated the approval of infigratinib (Truseltiq; QED Therapeutics), an oral kinase inhibitor, for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (CCA) and FGFR2 fusion or other rearrangement, as detected by an FDA-approved test.

The FDA granted infigratinib priority and fast-track review, as well as orphan drug designation for this indication. Infigratinib is the second targeted therapy approved by the FDA for this patient population.

On the same day, the FDA approved the FoundationOne CDx test as a companion diagnostic to infigratinib for selecting patients with CCA and FGFR2 fusion or other rearrangement for infigratinib treatment.

The approval of infigratinib was based on results from CBGJ398X2204, a multicenter, open-label, single-arm clinical trial of 108 patients with previously treated, unresectable locally advanced or metastatic CCA and an FGFR2 fusion or rearrangement. Patients received infigratinib 125 mg once daily for 21 days, followed by 7 days off, in 28-day cycles, until disease progression or unacceptable side effects.

The primary end points were overall response rate(ORR) and duration of response (DOR). The ORR was 23% (95% confidence interval [CI], 16-32), including 1 complete response and 24 partial responses. The median DOR was 5 months (95% CI, 3.7-9.3). Among the 23 patients who responded to therapy, the DOR was ≥6 months in 8 patients.

The most common (≥20%) adverse reactions were hyperphosphatemia, increased creatinine, nail toxicity, stomatitis, dry eye, fatigue, alopecia, palmar-plantar erythrodysesthesia syndrome, arthralgia, dysgeusia, constipation, abdominal pain, dry mouth, eyelash changes, diarrhea, dry skin, decreased appetite, blurred vision, and vomiting. Grade 3 or 4 adverse events included hyperphosphatemia and retinal pigment epithelial detachment.

Continued approval for this indication may be contingent on clinical benefit in confirmatory trial(s).

Related Items
Imbruvica Now Also Indicated for Children with Chronic Graft-versus-Host Disease
Web Exclusives published on November 17, 2022 in FDA Approvals
Pemazyre Receives New Indication for FGFR1-­Positive Myeloid/Lymphoid Neoplasms
Web Exclusives published on November 17, 2022 in FDA Approvals
Vegzelma a New Biosimilar FDA Approved for the Treatment of 6 Types of Cancer
Web Exclusives published on October 31, 2022 in FDA Approvals
Enhertu First FDA-Approved Drug for HER2-Positive Non–Small-Cell Lung Cancer
Web Exclusives published on October 31, 2022 in FDA Approvals
Enhertu First FDA-Approved Treatment for HER2-Low Breast Cancer
Web Exclusives published on October 31, 2022 in FDA Approvals
Last modified: November 9, 2021
Copyright © Engage Healthcare Communications, LLC. All rights reserved.